The proposed changes to the Medicare Shared Savings Program may put a damper on the accountable care organization (ACO) movement, but ACOs remain the government’s best option for controlling healthcare costs, said Stephen Nuckolls, CEO of Coastal Carolina Quality Care.
The proposed changes to the Medicare Shared Savings Program may put a damper on the accountable care organization (ACO) movement, but ACOs remain the government’s best option for controlling healthcare costs, said Stephen Nuckolls, CEO of Coastal Carolina Quality Care.
Transcript
What do you think the impact of the proposed MSSP changes will be on new ACOs looking to join?
I’m afraid from talking with many ACOs here at the conference [NAACOS fall 2018 meeting] and just looking at some of the responses that I’ve seen written, I think it is going to put a damper on the number that will be applying. I was speaking with one large well-known health system last night that had wished to enter the MSSP starting January 1. They’re here at the conference, but they’re not sure how their administrative department is going to take the 25% upside. While they are excited and optimistic about becoming an ACO, they’re not sure that the administration of the health system will allow that with the increased risk and also the lower rewards.
Do you think the proposed changes could hamper the ACO movement? Do you see more private payers stepping in to set up contracts?
I still think that the government’s best option for controlling healthcare costs is the accountable care organization and the standard fee-for-service Medicare. And I think that while there may be fewer ACOs in the program, and maybe a smaller number entering, I still think there will be a core that will continue to be there and will continue to be successful. And my hope would be that we would grow the movement, but that may take a longer period of time before we’re able to accomplish that.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most
March 13th 2025On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More